84 result(s) found
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
https://www.zacks.com/stock/news/2254812/novartis-nvs-inks-deal-for-arvn-s-prostate-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254812
Apr 12, 2024 - Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
0
Novartis (NVS) to Undertake Job Cuts in Development Department
https://www.zacks.com/stock/news/2253912/novartis-nvs-to-undertake-job-cuts-in-development-department?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253912
Apr 11, 2024 - Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
0
Novartis: Higher Guidance, Now A Buy
https://seekingalpha.com/article/4682065-novartis-stock-higher-guidance-now-buy-rating-upgrade?source=feed_all_articles
Apr 03, 2024 - Novartis reported solid 2023 financial results and increased its dividend per share. Click here to see why NVS stock is a Buy.
0
Novartis (NVS) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2249443/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249443
Apr 02, 2024 - In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.
0
Novartis (NVS) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2245727/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2245727
Mar 25, 2024 - In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.
0
Novartis (NVS) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2242497/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2242497
Mar 18, 2024 - In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
0
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0
AGFA Gevaert NV (AFGVF) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4678085-agfa-gevaert-nv-afgvf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 13, 2024 - AGFA Gevaert NV (OTCPK:AFGVF) Q4 2023 Earnings Conference Call March 13, 2024 6:00 AM ETCompany ParticipantsPascal Juery - President, CEO, President,...
0
Novartis to pay up to $835M for STING antagonist developer IFM Due
https://seekingalpha.com/news/4078969-novartis-to-pay-up-to-835m-for-sting-antagonist-developer-ifm-due?source=feed_sector_healthcare
Mar 13, 2024 - Novartis (NVS) has acquired IFM Due, a developer of STING antagonists, for $90M upfront and up to $745M in milestone payments. Read more here.
0
Are Consumer Staples Stocks Lagging Marine Harvest ASA (MHGVY) This Year?
https://www.zacks.com/stock/news/2239901/are-consumer-staples-stocks-lagging-marine-harvest-asa-mhgvy-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2239901
Mar 13, 2024 - Here is how Marine Harvest ASA (MHGVY) and Wolters Kluwer NV (WTKWY) have performed compared to their sector so far this year.
0